Journal
DEVELOPMENTAL BIOLOGY
Volume 462, Issue 2, Pages 197-207Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ydbio.2020.03.011
Keywords
Retinoblastoma; Human embryonic stem cells; Organoid; Retinal disease; CRISPR/Cas9; Cell cycle
Categories
Funding
- National Institutes of Health, United States [R01NS093992, R01NS089770, R01NS113516, R21AG066496]
- San Antonio Life Sciences Institute, United States
- Semmes Foundation, Inc., United States
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, United States
Ask authors/readers for more resources
Three-dimensional (3D) organoid models derived from human pluripotent stem cells provide a platform for studying human development and understanding disease mechanisms. Most studies that examine biallelic inactivation of the cell cycle regulator Retinoblastoma 1 (RB1) and the link to retinoblastoma is in mice, however, less is known regarding the pathophysiological role of RB1 during human retinal development. To study the role of RB1 in early human retinal development and tumor formation, we generated retinal organoids from CRISPR/Cas9-derived RB1-null human embryonic stem cells (hESCs). We showed that RB is abundantly expressed in retinal progenitor cells in retinal organoids and loss of RB1 promotes S-phase entry. Furthermore, loss of RB1 resulted in widespread apoptosis and reduced the number of photoreceptor, ganglion, and bipolar cells. Interestingly, RB1 mutation in retinal organoids did not result in retinoblastoma formation in vitro or in the vitreous body of NOD/SCID immunodeficient mice. Together, our work identifies a crucial function for RB1 in human retinal development and suggests that RB1 deletion alone is not sufficient for tumor development, at least in human retinal organoids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available